CTI BioPharma Corp. (NASDAQ:CTIC): Analysts Consensus Update

Equity investing typically requires extensive dedication and thourough research. To get ahead, investors need to examine every piece of information available. Sell-side Street analysts polled by Zacks Research have given a consensus target price of $0.75 on shares of CTI BioPharma Corp. (NASDAQ:CTIC). This number may be different from what First Call has listed for the consensus target estimate. Analysts that regularly cover the company may use varying techniques in order to arrive at a future target. Because of the different methods used, targets may vary widely between analysts. Right now, the range of targets using estimates from analysts polled by Zacks Research go from $0.75-$0.75. 

Covering equity analysts may also provide company stock ratings. Sell-side research firms may use different terminology when evaluating whether a stock should be pegged as a Buy, Sell, or Hold. Zacks Research offers an Average Broker Rating on company shares. This rating compiles recommendations from research analysts, and the resulting number resides on a scale between 1 and 5. Presently, CTI BioPharma Corp. has an ABR of 3.67. Following this rating scale, a score of 1 would represent a Strong Buy, and a score of 5 would indicate a Strong Sell. The average broker rating helps provide investors with a general feel of analyst sentiment on the stock.

Wall Street analysts are typically extra busy during earnings season. Prior to earnings, they are trying to correctly predict what a specific company will report. After earnings, they may be busy sifting through the earnings report and updating future company projections. Sell-side equity analysts are currently looking for the company to report quarterly EPS of $-0.07. Most recently, the company reported a quarterly earnings per share actual that landed $-0.03 away from what polled analysts were anticipating. This created a suprise factor of -42.86%. On or around 2017-02-21 is when the company is expected to next post earnings results.

The data in this report is in part provided by Zacks Research and Yahoo Finance.  The author does not have, nor plans to take any position in CTI BioPharma Corp. shares within the next 14 days.  Readers should not consider this as a recommendation to buy or sell company stock.  This piece is for informational purposes only.  Potentialy investors should always conduct full research before making investment decisions. 

Leave a Comment